Systemic lupus erythematosus evolving into rheumatoid arthritisROTHFIELD, Naomi F; LIM, Arnold A.Journal of rheumatology. 2006, Vol 33, Num 1, pp 188-190, issn 0315-162X, 3 p.Article

Factors associated with low bone mineral density in female patients with systemic lupus erythematosusLAKSHMINARAYANAN, Santhanam; WALSH, Stephen; MOHANRAJ, Mirna et al.Journal of rheumatology. 2001, Vol 28, Num 1, pp 102-108, issn 0315-162XArticle

Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trialMAYES, Maureen D; O'DONNELL, Daniel; ROTHFIELD, Naomi F et al.Arthritis and rheumatism. 2004, Vol 50, Num 2, pp 553-557, issn 0004-3591, 5 p.Article

Progression of Esophageal Dysmotility in Systemic SclerosisVISCHIO, John; SAEED, Fahd; KARIMEDDINI, Mozafareddin et al.Journal of rheumatology. 2012, Vol 39, Num 5, pp 986-991, issn 0315-162X, 6 p.Article

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Type I Collagen Treatment in Patients With Diffuse Cutaneous Systemic Sclerosis I. Oral Type I Collagen Does Not Improve Skin in All Patients, but May Improve Skin in Late-Phase DiseasePOSTLETHWAITE, Arnold E; WENG KEEWONG; MORELAND, Larry et al.Arthritis and rheumatism. 2008, Vol 58, Num 6, pp 1810-1822, issn 0004-3591, 13 p.Article

Cyclophosphamide versus placebo in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.The New England journal of medicine. 2006, Vol 354, Num 25, pp 2655-2666, issn 0028-4793, 12 p.Article

A comparison of self-reports of distress and affective disorder diagnoses in rheumatoid arthritis: A receiver operator characteristic analysisMCQUILLAN, Julia; FIFIELD, Judith; SHEEHAN, T. Joseph et al.Arthritis care and research. 2003, Vol 49, Num 3, pp 368-376, issn 0893-7524, 9 p.Article

MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon : A Randomized, Controlled TrialCHUNG, Lorinda; SHAPIRO, Lee; SMITH, Edwin et al.Arthritis and rheumatism. 2009, Vol 60, Num 3, pp 870-877, issn 0004-3591, 8 p.Article

Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Cutaneous Involvement : A Randomized, Double-Blind, Placebo-Controlled TrialKHANNA, Dinesh; CLEMENTS, Philip J; STEEN, Virginia D et al.Arthritis and rheumatism. 2009, Vol 60, Num 4, pp 1102-1111, issn 0004-3591, 10 p.Article

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.American journal of respiratory and critical care medicine. 2007, Vol 176, Num 10, pp 1026-1034, issn 1073-449X, 9 p.Article

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease : Results from the scleroderma lung studyKHANNA, Dinesh; XIAOHONG YAN; RILEY, David J et al.Arthritis and rheumatism. 2007, Vol 56, Num 5, pp 1676-1684, issn 0004-3591, 9 p.Article

Reduced exercise capacity and stress-induced pulmonary hypertension in patients with sclerodermaLUAY ALKOTOB, M; SOLTANI, Peyman; SHEATT, Mohammad A et al.Chest. 2006, Vol 130, Num 1, pp 176-181, issn 0012-3692, 6 p.Article

Responsiveness of the SF-36 and the health assessment questionnaire disability index in a systemic sclerosis clinical trialKHANNA, Dinesh; FURST, Daniel E; MORELAND, Larry W et al.Journal of rheumatology. 2005, Vol 32, Num 5, pp 832-840, issn 0315-162X, 9 p.Article

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody contentTAN, Eng M; SMOLEN, Josef S; ROTHFIELD, Naomi F et al.Journal of rheumatology. 2002, Vol 29, Num 1, pp 68-74, issn 0315-162XArticle

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonMERKEL, Peter A; HERLYN, Karen; ROTHFIELD, Naomi F et al.Arthritis and rheumatism. 2002, Vol 46, Num 9, pp 2410-2420, issn 0004-3591, 11 p.Article

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratoriesFRITZLER, Marvin J; WIIK, Allan; MAINI, Ravinder N et al.Journal of rheumatology. 2003, Vol 30, Num 11, pp 2374-2381, issn 0315-162X, 8 p.Article

Outcome measurements in scleroderma : Results from a delphi exerciseGAZI, Hashim; POPE, Janet E; EMERY, Paul et al.Journal of rheumatology. 2007, Vol 34, Num 3, pp 501-509, issn 0315-162X, 9 p.Article

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis results from the scleroderma lung studyKHANNA, Dinesh; CLEMENTS, Philip J; VARGA, John et al.Arthritis and rheumatism. 2005, Vol 52, Num 2, pp 592-600, issn 0004-3591, 9 p.Article

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: Results of a multicenter randomized, double-blind, placebo-controlled trialPETRI, Michelle A; MEASE, Philip J; VAN VOLLENHOVEN, Ronald et al.Arthritis and rheumatism. 2004, Vol 50, Num 9, pp 2858-2868, issn 0004-3591, 11 p.Article